Cargando…

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Detalles Bibliográficos
Autores principales:	Kuo, Yuan-Hung, Lu, Sheng-Nan, Chen, Yen-Yang, Kee, Kwong-Ming, Yen, Yi-Hao, Hung, Chao-Hung, Hu, Tsung-Hui, Chen, Chien-Hung, Wang, Jing-Houng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712880/ https://www.ncbi.nlm.nih.gov/pubmed/34970502 http://dx.doi.org/10.3389/fonc.2021.823960

Ejemplares similares

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Chiang, Hsueh-Chien, et al.
Publicado: (2023)

Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib
por: Kuo, Yuan-Hung, et al.
Publicado: (2022)

Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib
por: Kee, Kwong-Ming, et al.
Publicado: (2014)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data
por: Yen, Yi-Hao, et al.
Publicado: (2019)

Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation
por: Chen, Hsin-Yeh, et al.
Publicado: (2020)

Hepatic Clostridium Perfringens Abscess Formation after Radiofrequency Ablation Therapy for Hepatocellular Carcinoma: Report of a Rare Case
por: Wang, Ming-Hung, et al.
Publicado: (2021)

A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort
por: Yen, Yi-Hao, et al.
Publicado: (2018)

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
por: Rimini, M., et al.
Publicado: (2022)

Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation
por: Yao, Chih-Chien, et al.
Publicado: (2023)

Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation
por: Kuo, Yuan-Hung, et al.
Publicado: (2023)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
por: Choi, Na Ryung, et al.
Publicado: (2022)

Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment
por: Yeh, Jen-Hao, et al.
Publicado: (2015)

Low-dose nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2022)

Ultrasound is highly specific in diagnosing compensated cirrhosis in chronic hepatitis C patients in real world clinical practice
por: Yen, Yi-Hao, et al.
Publicado: (2019)

Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy
por: Huang, Pao-Yuan, et al.
Publicado: (2019)

Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study
por: Peng, Tzu-Rong, et al.
Publicado: (2021)

Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C
por: Yen, Yi-Hao, et al.
Publicado: (2019)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
por: Lee, I-Cheng, et al.
Publicado: (2022)

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
por: Chen, San-Chi, et al.
Publicado: (2022)

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
por: Wang, Jing-Houng, et al.
Publicado: (2022)

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
por: Wu, Wen-Chi, et al.
Publicado: (2022)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
por: Fan, Wenzhe, et al.
Publicado: (2022)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level
por: Yen, Yi-Hao, et al.
Publicado: (2018)

A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation
por: Hung, Chao-Hung, et al.
Publicado: (2017)

Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis
por: Chen, Jinbin, et al.
Publicado: (2018)

Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West
por: Yen, Yi-Hao, et al.
Publicado: (2020)

Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population
por: Lee, Shou-Wu, et al.
Publicado: (2022)

Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study
por: Mei, Jie, et al.
Publicado: (2020)

Surgical resection significantly promotes the overall survival of patients with hepatocellular carcinoma: a propensity score matching analysis
por: Chen, Yaw-Sen, et al.
Publicado: (2021)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral
por: Chang, Kuo-Chin, et al.
Publicado: (2022)

Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis
por: Lin, Chih-Wen, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score–Matched Analysis
por: Chen, Yu-Xing, et al.
Publicado: (2022)

Concurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma: A Propensity-Matched Analysis
por: Liu, Chieh-Min, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sgu04079nsps4dt6d1d9ons00j